Madhushree Bhattacharya

Madhushree Bhattacharya

Auto-generated profile, based on publicly available information

Madhushree Bhattacharya

Centre for Drug Research, Division of Pharmaceutical Biosciences, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
EAEva Maria del Amo
Eva Maria del Amo
ARAnna-Kaisa Rimpelä
Anna-Kaisa Rimpelä
EHEmma Heikkinen
Emma Heikkinen
OKOtto K. Kari
Otto K. Kari
EREva Ramsay
Eva Ramsay
AUArto Urtti
Arto Urtti
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.

1 December 2012 in Journal of Controlled Release
Verified
Journal Article
Open access
MBMadhushree Bhattacharya
Madhushree Bhattacharya
MMMelina M. Malinen
Melina M. Malinen
PLPatrick Laurén
Patrick Laurén
Yan-Ru LouYan-Ru Lou
Yan-Ru Lou
SKSaara W. Kuisma
Saara W. Kuisma
MYMarjo Yliperttula
Marjo Yliperttula
Over the recent years, various materials have been introduced as potential 3D cell culture scaffolds. These include protein extracts, peptide amphiphiles, and synthetic polymers. Hydrogel scaffolds without human or animal borne components or added bioactive components are preferred from the immunological point of view. Here we demonstrate that native nanofibrillar cellulose (NFC) hydrogels derived from the abundant plant sources provide the desired functionalities. We show 1) rheological properties that allow formation of a 3D scaffold in-situ after facile injection, 2) cellular biocompatibility without added growth factors, 3) cellular polarization, and 4) differentiation of human hepatic cell lines HepaRG and HepG2. At high shear stress, the aqueous NFC has small viscosity that supports injectability, whereas at low shear stress conditions the material is converted to an elastic gel. Due to the inherent biocompatibility without any additives, we conclude that NFC generates a feasible and sustained microenvironment for 3D cell culture for potential applications, such as drug and chemical testing, tissue engineering, and cell therapy.

1 November 2020 in Journal of Controlled Release
Verified
Journal Article
Open access
MBMadhushree Bhattacharya
Madhushree Bhattacharya
ASAmir Sadeghi
Amir Sadeghi
SSSanjay Sarkhel
Sanjay Sarkhel
MHMarja Hagström
Marja Hagström
SBSina Bahrpeyma
Sina Bahrpeyma
AUArto Urtti
Arto Urtti
Tissue barriers limit drug delivery in the eye. Therefore, retinal diseases are treated with intravitreal injections. Delivery systems with reduced dosing frequency and/or cellular drug delivery properties are needed. We present here a modular peptide-based delivery system for cell targeted release of dexamethasone in the retinal pigment epithelial cells. The peptide-dexamethasone conjugates consist of cell penetrating peptide, enzyme cleavable linker and dexamethasone that is conjugated with hydrazone bond. The conjugates are chemically stable in the vitreous, internalize into the retinal pigment epithelial cells and release dexamethasone intracellularly by enzymatic action of cathepsin D. In vitro binding assay and molecular docking confirm binding of the released dexamethasone fragment to the human glucocorticoid receptor. In vivo rabbit studies show increased vitreal retention of dexamethasone with a peptide conjugate. Modular peptide conjugates are a promising approach for drug delivery into the retinal cells.

1 April 2017 in Journal of Controlled Release
Verified
Journal Article
Open access
MBMadhushree Bhattacharya
Madhushree Bhattacharya
SSSanjay Sarkhel
Sanjay Sarkhel
JPJonne Peltoniemi
Jonne Peltoniemi
RBRobert Broadbridge
Robert Broadbridge
MTMarjo Tuomainen
Marjo Tuomainen
AUArto Urtti
Arto Urtti
Currently, drug delivery to the posterior eye segment relies on intravitreal injections of therapeutics. This approach requires frequent injections and does not guarantee drug delivery to intracellular targets. Controlled release systems and nanoparticles are being investigated to mitigate these challenges but most of these approaches lack translational success to the clinics. In our present study, we report a peptide-based delivery system that utilizes enzyme assisted cleavable linkers to release conjugated cargo within the retinal pigment epithelial (RPE) cells. Peptide linkers with differential cleavage rates were developed and tested in the vitreous humor, RPE cell homogenates and intact RPE cells. Selected peptide linkers were conjugated to cell penetrating peptides and d-peptide cargoes. The peptide-based delivery systems were non-toxic to the RPE cells, chemically stable in porcine vitreous and delivered cargo prototypes (hydrophobic & hydrophilic) to the RPE cells. Importantly, we show quantitatively with LC/MS analytics that the intracellular cargo release is controlled by the sequence of the peptide linker. The controlled cleavage of the peptide linkers is not only a useful strategy for intracellular drug delivery to the RPE targets but might also be useful in utilizing the RPE cells as mediators of drug delivery to intracellular targets and surrounding tissues (such as neural retina and choroid).

1 January 2006 in Biochemistry
Verified
Journal Article
Open access
TITetsuya Ishino
Tetsuya Ishino
UPUdaya Pillalamarri
Udaya Pillalamarri
DPDominick Panarello
Dominick Panarello
MBMadhushree Bhattacharya
Madhushree Bhattacharya
CUCecilia Urbina
Cecilia Urbina
ICIrwin Chaiken
Irwin Chaiken
The cyclic peptide AF17121 (VDECWRIIASHTWFCAEE) is a library-derived antagonist for human Interleukin-5 receptor α (IL5Rα). We have previously demonstrated that AF17121 mimics Interleukin-5 (IL5) by binding in a region of IL5Rα that overlaps the IL5 binding epitope. In the present study, to explore the functional importance of the amino acid residues of AF17121 required for effective binding to, and antagonism of, IL5Rα, each charged residue was subjected to site-directed mutagenesis and examined for IL5Rα interaction by using a surface plasmon resonance biosensor. One residue, Arg6, was found to be essential for receptor antagonism; its replacement with either alanine or lysine completely abolished the interaction between AF17121 and IL5Rα. Other charged residues play modulatory roles. One class consists of the N-terminal acidic cluster (Asp2 and Glu3) for which alanine replacement decreased the association rate. A second class consists of His11 and the C-terminal acidic cluster (Glu17 and Glu18) for which alanine replacement increased the dissociation rate. Binding model analysis of the mutants of the latter class of residues indicated the existence of conformational rearrangement during the interaction. On the basis of these results, we propose a model in which Arg6 and N-terminal acidic residues drive the encounter complex, while Arg6, His11, and C-terminal acidic residues are involved in stabilizing the final complex. These data argue that the charged residues of AF17121 are utilized asymmetrically in the pathway of inhibitor−receptor complex formation to deactivate the receptor function. The results also help focus emerging models for the mechanism by which IL5 activates the IL5Rα−βc receptor system.

1 January 1999 in Journal of Chemical Research
Verified
Journal Article
Closed access
PDF file
TNT. Naqvi
T. Naqvi
MBM. Bhattacharya
M. Bhattacharya
WHW. Haq
W. Haq
Reduction of pentachlorophenyl esters of Boc protected amino acids and peptides to the corresponding alcohols is described.